Get the Stockscreener App
23.49
0.17%
0.04
After Hours:
23.53
0.04
+0.17%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $23.49, with a volume of 56.58M.
It is up +0.17% in the last 24 hours and down -1.26% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$23.45
Open:
$23.48
24h Volume:
56.58M
Relative Volume:
1.14
Market Cap:
$133.55B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
17.02
EPS:
1.38
Net Cash Flow:
$11.22B
1W Performance:
+0.73%
1M Performance:
-1.26%
6M Performance:
-10.38%
1Y Performance:
-16.70%
1-Day Range:
$23.16
$23.62
1-Week Range:
$23.11
$23.66
52-Week Range:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.49 | 132.58B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
737.67 | 640.72B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.21 | 367.98B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.11 | 323.71B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.76 | 222.69B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.50 | 299.26B | 43.59B | 15.04B | 10.74B | 3.3766 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer CEO: HHS claims of ‘concealed safety concerns’ on mRNA vaccines are ‘completely inaccurate’ - WAAY 31 News
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters
Pfizer and Arvinas Plan FDA Submission for Breast Cancer Drug - GuruFocus
Pfizer, Arvinas report positive breast cancer drug trial - breakingthenews.net
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2 - Seeking Alpha
Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression - WSAU
Arvinas And Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival For Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer - marketscreener.com
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progre - GuruFocus
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer - BioPharma Dive
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - GlobeNewswire
Pfizer Combo Halves Death Risk in BRAF V600E Cancer - Mirage News
US CDC keeps COVID vaccine option for healthy children - marketscreener.com
Pfizer Reports Positive Results in Late Stage Trial for Colorectal Cancer Treatment - Insider Monkey
Former Pfizer Atty, Motley Rice Adviser, Joins DiCello Levitt - Law360
Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50% - Benzinga
US CDC continues to recommend COVID vaccines for children, contradicts Kennedy - marketscreener.com
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC - Yahoo Finance
Pfizer: colorectal cancer mortality halved - marketscreener.com
Pfizer posts trial win for colorectal cancer drug (PFE:NYSE) - Seeking Alpha
Pfizer Says Braftovi Combination Regimen Halved Death Risk in Colorectal Cancer Study - marketscreener.com
Pfizer's Oral Obesity Drug FlopA Symptom Of A Deeper Pipeline Problem - Seeking Alpha
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - Pfizer
Pfizer Says Braftovi Combination Regimen Met Trial's Dual Primary Endpoint - marketscreener.com
Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show - MedCity News
Pfizer’s Braftovi Doubles Survival in Advanced Colorectal Cancer - Bloomberg
The World Market for Smoking Cessation & Nicotine De-Addiction Products 2025-2030: Precision Counseling, Targeted Pharmacogenomic Therapies, and Resilient Supply Chains Present Lucrative Opportunities - GlobeNewswire Inc.
$3.94 Bn IV Hydration Therapy Markets - GlobeNewswire Inc.
Why this $400-million money manager is ditching Pfizer and buying the tech dip - The Globe and Mail
FDA Warns of Heart Risk With Pfizer, Moderna COVID Vaccines - Hematology Advisor
Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes - Yahoo Finance
Pfizer (NYSE:PFE) Ends Collaboration With Acepodia And Faces Depo-Provera Legal Challenges - simplywall.st
Pfizer Jolted Higher On A Merck-Rivaling Deal. Is It A Buy? - Investor's Business Daily
Pfizer (PFE) Down 5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Are Investors Undervaluing Pfizer (PFE) Right Now? - Nasdaq
Down 63%, Should You Buy the Dip on Pfizer? - AOL.com
Berenberg Bank Cuts Pfizer Price Target to $25 From $28, Maintains Hold Rating - marketscreener.com
5 Rock-Solid Dividend Stocks Under $50 With Room to Run - 24/7 Wall St.
Old COVID tweet lands Pfizer in new trouble with PMCPA - pharmaphorum
PFIZER INC : Berenberg reaffirms its Neutral rating - marketscreener.com
Acute Myeloid Leukemia Market Detailed Analysis and Forecast - openPR.com
Pfizer (PFE) Stock Slides Over 2%, Hits Day’s Low in Afternoon Trading - Daily Chhattisgarh News
With 67% ownership of the shares, Pfizer Inc. (NYSE:PFE) is heavily dominated by institutional owners - Yahoo Finance
U.S. Vaccine Market Set to Witness Robust ExpansionPfizer, Moderna - openPR.com
Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development - marketscreener.com
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline - Seeking Alpha
US drops COVID vaccine recommendation for healthy kids, pregnant women - marketscreener.com
Mixed options sentiment in Pfizer with shares up 0.88% - TipRanks
US drops COVID vaccine recommendations for healthy children, pregnant women - marketscreener.com
Sleep Aids Market Generated Opportunities, Future Scope - openPR.com
Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):